Rose Carlos D
Division of Rheumatology, Nemours Alfred I. duPont Hospital for Children, Thomas Jefferson University, Wilmingtom, Delaware; and Chair, Nemours Wilmington Institutional Review Board, Nemours Office of Human Research Protection, Wilmington, Delaware
Pediatrics. 2017 May;139(5). doi: 10.1542/peds.2016-3648. Epub 2017 Apr 7.
As human experimentation continues to grow into an ever more complex and sophisticated endeavor, the relevant ethical and regulatory structures become more intricate. When pediatricians and general practitioners are invited by pharmaceutical companies to enroll their offices in a clinical trial or a multicenter observational study or when they develop their own research questions, they frequently find themselves at a loss in the human research environment. The legal and regulatory complexity may have an unintended deterring effect at a time when office-based high quality pediatric research is urgently needed to support evidence-based medicine. Unfortunately, in many instances, unaware practitioners become involved in low-risk research activities without knowing it and become entangled in legal, auditing, and compliance procedures. This paper, written in 2 parts, aims at providing a general guidance on the principles that regulate human research with a focus on pediatrics. Part 1 discusses the history, the legal framework, and the consent process and highlights some practical aspects of initial protocol submission, continued review, and institutional review board determinations with the main focus on multicenter clinical trials (industry-sponsored research). Part 2 focuses on pediatric research regulation, also known as subpart-D, and minimal risk research, which encompasses many research activities aimed at addressing questions that may emerge in pediatricians' practices (investigator-initiated research).
随着人体实验不断发展成为一项日益复杂和精细的活动,相关的伦理和监管结构也变得更加错综复杂。当制药公司邀请儿科医生和全科医生在其诊所开展临床试验或多中心观察性研究,或者当他们提出自己的研究问题时,他们常常在人体研究环境中感到不知所措。在迫切需要基于办公室的高质量儿科研究来支持循证医学之际,法律和监管的复杂性可能会产生意想不到的阻碍作用。不幸的是,在许多情况下,不知情的从业者在不知不觉中参与了低风险研究活动,并陷入了法律、审计和合规程序之中。本文分为两部分,旨在提供有关规范人体研究原则的一般指导,重点是儿科。第一部分讨论了历史、法律框架和知情同意过程,并强调了初始方案提交、持续审查以及机构审查委员会决定的一些实际方面,主要侧重于多中心临床试验(行业资助的研究)。第二部分重点关注儿科研究监管,也称为D子部分,以及最小风险研究,其中包括许多旨在解决儿科医生临床实践中可能出现问题的研究活动(研究者发起的研究)。